Cladis Investment Advisory LLC Purchases 1,265 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Cladis Investment Advisory LLC lifted its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 41.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,300 shares of the financial services provider’s stock after buying an additional 1,265 shares during the period. Cladis Investment Advisory LLC’s holdings in iShares Biotechnology ETF were worth $626,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of iShares Biotechnology ETF by 29.3% during the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after buying an additional 538,899 shares during the last quarter. Commerce Bank grew its position in iShares Biotechnology ETF by 1.8% during the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock worth $108,234,000 after acquiring an additional 12,921 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares during the period. Main Management ETF Advisors LLC lifted its position in iShares Biotechnology ETF by 2.6% in the second quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after purchasing an additional 14,535 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of iShares Biotechnology ETF by 24.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after purchasing an additional 42,822 shares during the period. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.0 %

Shares of NASDAQ IBB opened at $141.55 on Monday. The firm’s fifty day moving average is $142.71 and its 200 day moving average is $142.06. iShares Biotechnology ETF has a 52 week low of $119.95 and a 52 week high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Shareholders of record on Wednesday, September 25th were given a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.